Tas-ox

Description

TAS-OX is a combination regimen of trifluridine/tipiracil (TAS-102, also known as Lonsurf) plus oxaliplatin, investigated for the treatment of metastatic colorectal cancer (mCRC). This combination has been studied primarily in patients with refractory mCRC who have progressed on prior standard therapies including fluoropyrimidines, irinotecan, oxaliplatin, anti-VEGF agents, and anti-EGFR agents (if RAS wild-type). Clinical trials, including the phase II TASCC trial, have explored whether adding oxaliplatin to TAS-102 can improve outcomes compared to TAS-102 alone, showing promising progression-free survival signals in the later-line setting. TAS-OX represents an emerging strategy to enhance the activity of TAS-102 in heavily pretreated mCRC patients.

Mechanism of Action

Trifluridine is a thymidine-based nucleoside analogue that is incorporated into DNA, causing DNA dysfunction and inhibiting cell proliferation; tipiracil inhibits thymidine phosphorylase to prevent rapid degradation of trifluridine. Oxaliplatin is a platinum-based agent that forms inter- and intra-strand DNA crosslinks, inhibiting DNA replication and transcription, and the combination provides complementary cytotoxic mechanisms.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials